Innovative drug-delivery systems and combination products have the potential to play an important role in the future of interventional cardiology. Improvements in coating technology (uniformity, conformity, control of drug morphology) - along with the potential use of other classes of active therapeutic agents - may enhance Micell's ability to contribute safer, more efficacious devices and treatments.

Micell's supercritical fluid-based technology platform has the potential to provide control over both drug morphology and the ability to apply multiple therapeutic agents discretely and independently in single or multiple layers to achieve tailored therapeutics.